Table 3 Common adverse events (≥5% of patients in any group; safety population)
From: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Adverse event, N(%) | Quetiapine 300 mg/day (n = 298) | Quetiapine 600 mg/day (n = 307) | Placebo (n = 214) |
|---|---|---|---|
Dry mouth | 94 (31.5) | 90 (29.3) | 21 (9.8) |
Somnolence | 65 (21.8) | 60 (19.5) | 18 (8.4) |
Sedation | 60 (20.1) | 59 (19.2) | 12 (5.6) |
Dizziness | 39 (13.1) | 48 (15.6) | 12 (5.6) |
Headache | 27 (9.1) | 37 (12.1) | 40 (18.7) |
Fatigue | 26 (8.7) | 30 (9.8) | 14 (6.5) |
Constipation | 24 (8.1) | 24 (7.8) | 9 (4.2) |
Nausea | 23 (7.7) | 22 (7.2) | 21 (9.8) |
Diarrhea | 12 (4.0) | 8 (2.6) | 17 (7.9) |
Insomnia | 8 (2.7) | 2 (0.7) | 14 (6.5) |
Upper respiratory tract infection | 7 (2.3) | 7 (2.3) | 11 (5.1) |